Press release regarding audited financial results of FY26.
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fermenta Biotech reported FY26 consolidated revenue of INR 547.8 crore, up 14% YoY; excluding real estate, revenue was INR 538.4 crore, up 26% YoY. EBITDA (excluding real estate) grew 44% YoY to INR 120 crore, reflecting strong operational leverage. PAT was INR 70.3 crore, down 8% YoY, but this decline is due to a high FY25 base from INR 44.6 crore of one-time real estate value-unlocking income. Adjusted for this one-off, underlying PAT was materially higher, consistent with the EBITDA growth. The company recorded two exceptional items: a INR 9.07 crore write-back of provisions and a INR 2.19 crore employee-benefit charge from new Labour Codes. Key growth drivers were Vitamin D3 Human Nutrition (+28% YoY), Vitamin D3 Animal Nutrition (+32% YoY), and Green Chemistry Solutions (+126% YoY). The board recommended a dividend of INR 3.75 per share.
While headline PAT declined 8%, the underlying operating performance is strong with 44% EBITDA growth excluding one-off real estate income, indicating improved business quality and operational efficiency. The stock should be viewed positively given robust core business growth.